Abstract: Research tool assay for identifying a specific modulator of GNAI, compositions and methods of use. The assay includes combining a drug candidate with GNAI and a C-terminal GIV peptide and determining if the drug candidate inhibits GNAI interaction with the C-terminal GIV peptide; and combining the drug candidate with GNAI and a DAPLE peptide and determining if the drug candidate inhibits GNAI interaction with DAPLE peptide. Also provided are compositions and methods of treatment relating to the same.

Abstract: The present invention provides a Fluorescence Resonance Energy Transfer (FRET) biosensor that measures the metastatic potential and/or chemoresistance of single living cancer cells, and/or cells associated with fibrogenesis, diabetes, aging, and/or infertility.

Abstract: Methods to interrogate and modulate gut barrier integrity are provided. Methods for treating leaky gut barrier are also provided. Methods for early detection of diseases associated with inflammatory disorders. Methods to rapidly assess the effects of drugs, chemicals, nutritional supplements, vitamins, and probiotics on the integrity of the gut barrier are also provided.

Abstract: The invention provides cell-permeable Ga-Interacting Vesicle associated protein (GIV)-derived peptides and their use for treatment of diverse diseases. The invention further provides C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT)-based peptides and GIV-CT encoding vectors and methods of use thereof, for successfully manipulating the diverse pathophysiologic processes in which GIV has been implicated. In one aspect, the invention provides cell-permeable peptides PTD-GIV-CT comprising (i) a peptide transduction domain (PTD) and (ii) a C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT) or a mutant thereof. In one embodiment, said peptides are capable of activating Gi downstream of receptor tyrosine kinases (RTKs). The invention also provides pharmaceutical compositions comprising one or more of the peptides of the invention as well as vectors encoding such peptides.

Abstract: Research tool assay for identifying a specific modulator of GNAI, compositions and methods of use. The assay includes combining a drug candidate with GNAI and a C-terminal GIV peptide and determining if the drug candidate inhibits GNAI interaction with the C-terminal GIV peptide; and combining the drug candidate with GNAI and a DAPLE peptide and determining if the drug candidate inhibits GNAI interaction with DAPLE peptide. Also provided are compositions and methods of treatment relating to the same.

Abstract: The invention provides DAPLE as a novel regulator of G protein activity and its diagnostic and therapeutic use in cancer.

Abstract: The invention provides cell-permeable Ga-Interacting Vesicle associated protein (GIV)-derived peptides and their use for treatment of diverse diseases. The invention further provides C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT)-based peptides and GIV-CT encoding vectors and methods of use thereof, for successfully manipulating the diverse pathophysiologic processes in which GIV has been implicated. In one aspect, the invention provides cell-permeable peptides PTD-GIV-CT comprising (i) a peptide transduction domain (PTD) and (ii) a C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT) or a mutant thereof. In one embodiment, said peptides are capable of activating Gi ownstream of receptor tyrosine kinases (RTKs). The invention also provides pharmaceutical compositions comprising one or more of the peptides of the invention as well as vectors encoding such peptides.

Abstract: Provided herein are methods of analyzing stage II colorectal cancer (CRC) samples (such as those that are mis-match repair proficient, pMMR), by scoring G-alpha interacting vesicle associated protein (GIV, also known as girdin) full-length (GIV-fl) expression in combination with lymphovascular invasion (LVI) status or clinical variables. The disclosed methods can be used to identify GIV-fl expressing tumors that are likely to recur (high risk) and those that are not likely to recur (high risk). Subjects identified as having a high risk CRC can be selected to receive chemotherapy or biotherapy for the CRC. Thus, in some examples, the disclosed methods can be used to identify CRC tumors that are likely to respond to chemotherapy or biotherapy. Also provided are computer implemented methods, systems, and kits that can be used with these methods.

Abstract: The present disclosure generally relates to tyrosine phosphorylation sites of an Akt enhancer, and methods for the detection of the phosphorylated tyrosine residues. In particular, anti-phosphotyrosine antibodies and binding proteins find use in the compositions and methods of the present disclosure.

Abstract: The invention provides DAPLE as a novel regulator of G protein activity and its diagnostic and therapeutic use in cancer.

Abstract: The present disclosure generally relates to tyrosine phosphorylation sites of an Akt enhancer, and methods for the detection of the phosphorylated tyrosine residues. In particular, anti-phosphotyrosine antibodies and binding proteins find use in the compositions and methods of the present disclosure.

Abstract: A method is provided for analyzing a test vector for use in measuring static current consumed by an integrated circuit that has an embedded memory device. According to the method, a potential test vector is applied to a functional model of the integrated circuit. The logic states of various nodes in the integrated circuit are detected in response to the potential test vector. At least some of the nodes correspond to the input address bits of the memory device, where the memory device has a valid address range on the input address bits. An output is produced for the potential test vector based on whether these logic states correspond to an address within the valid address range.

Abstract: A method and apparatus are provided for analyzing test vectors for use in measuring static current consumed by an integrated circuit. A netlist of interconnected cells is read to identify cell types used within the netlist, wherein the netlist includes a plurality of nodes. Once the netlist has been read, cell characteristics for selected ones of the cell types are read from a technology library to identify pins of the selected cell types to be monitored. The nodes in the netlist that correspond to these pins are identified and are added to an list file. Once the list file has been generated, a computer simulation program is used to simulate a steady-state response of a functional model of the integrated circuit to a potential test vector and to output the resulting logic states on the nodes provided in the list file.